Retrospective Cohort Study
Copyright ©The Author(s) 2023.
World J Diabetes. Jul 15, 2023; 14(7): 1091-1102
Published online Jul 15, 2023. doi: 10.4239/wjd.v14.i7.1091
Table 3 Crude and adjusted hazard ratio associated with each predictor
Item
Crude HR (95%CI)
Adjusted HR (95%CI)
Quality-of-care score
Score ≤ 111
1 < Score < 50.69 (0.55-0.88)0.71 (0.55-0.90)
Score ≥ 50.36 (0.20-0.63)0.37 (0.21-0.66)
Age
≤ 4011
40 < Age ≤ 651.93 (1.12-3.32)1.90 (1.10-3.28)
> 652.64 (1.51-4.62)2.48 (1.39-4.40)
Sex
Male 11
Female0.57 (0.45-0.73)0.53 (0.42-0.67)
Anti-diabetic drugs
Oral only11
Insulin only0.80 (0.60-1.07)0.78 (0.59-1.05)
Oral + insulin0.70 (0.49-1.01)0.77 (0.54-1.11)
Adherence to medication (%)
< 900.89 (0.69-1.15)0.79 (0.61-1.02)
90 ≤ adherence < 11011
≥ 1100.71 (0.37-1.37)0.66 (0.34-1.28)
Comorbidity (DCSI)
011
11.13 (0.83-1.54)0.95 (0.69-1.31)
21.31 (0.94-1.81)1.02 (0.72-1.43)
31.27 (0.69-2.33)0.96 (0.52-1.80)
41.56 (0.73-3.31)1.07 (0.49-2.31)
≥ 51.04 (0.15-7.43)0.66 (0.09-4.77)
Hypertension/dyslipidemia
None11
Hypertension only1.38 (1.07-1.78)1.30 (0.99-1.71)
Dyslipidemia only1.19 (0.64-2.18)1.17 (0.64-2.17)
Both1.89 (1.27-2.79)1.82 (1.20-2.75)